[Hematological toxicity and risk factors in relapsed/refractory multiple myeloma patients after CAR-T therapy].
作者信息
Zhao T T, Ge J, Zhu H, Ma R B, Li C Y, Wan C Y, Wang Y, Xu K L, Li Z Y
机构信息
Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):858-860. doi: 10.3760/cma.j.issn.0253-2727.2022.10.010.
Abstract
摘要
相似文献
1
[Hematological toxicity and risk factors in relapsed/refractory multiple myeloma patients after CAR-T therapy].[嵌合抗原受体T细胞（CAR-T）治疗后复发/难治性多发性骨髓瘤患者的血液学毒性及危险因素]
Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):858-860. doi: 10.3760/cma.j.issn.0253-2727.2022.10.010.
2
Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤患者接受成熟抗原（BCMA）嵌合抗原受体（CAR）-T细胞（HDS269B）治疗后的后续抗骨髓瘤治疗。
Am J Hematol. 2022 Dec;97(12):E478-E481. doi: 10.1002/ajh.26745. Epub 2022 Oct 17.
3
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
4
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need.嵌合抗原受体 T 细胞疗法在复发/难治性大细胞淋巴瘤和多发性骨髓瘤中的失败：一个亟待满足的未满足需求。
Blood Rev. 2023 Jul;60:101095. doi: 10.1016/j.blre.2023.101095. Epub 2023 Apr 29.
5
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.伊达基奥仑赛（ide-cel）嵌合抗原受体 T 细胞疗法治疗复发/难治性多发性骨髓瘤。
Future Oncol. 2022 Jan;18(3):277-289. doi: 10.2217/fon-2021-1090. Epub 2021 Dec 2.
6
Clinical experience of CAR T cells for multiple myeloma.嵌合抗原受体T细胞治疗多发性骨髓瘤的临床经验
Best Pract Res Clin Haematol. 2021 Sep;34(3):101306. doi: 10.1016/j.beha.2021.101306. Epub 2021 Aug 28.
7
CAR T cell therapy for multiple myeloma: where are we now and where are we headed?嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：我们目前的状况及未来走向？
Leuk Lymphoma. 2018 Sep;59(9):2056-2067. doi: 10.1080/10428194.2017.1393668. Epub 2017 Nov 6.
8
Chimeric antigen receptor T cell therapies for multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤。
J Hematol Oncol. 2019 Nov 21;12(1):120. doi: 10.1186/s13045-019-0823-5.
9
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.嵌合抗原受体 T 细胞疗法治疗复发/难治性免疫球蛋白 D 多发性骨髓瘤的疗效和安全性。
Transplant Cell Ther. 2021 Mar;27(3):273.e1-273.e5. doi: 10.1016/j.jtct.2020.12.017. Epub 2020 Dec 19.
10
[New Research Advances on Chimeric Antigen Receptor T Cells in the Treatment of Relapsed and Refractory Multiple Myeloma-Review].嵌合抗原受体T细胞治疗复发难治性多发性骨髓瘤的新研究进展——综述
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1316-1320. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.053.
本文引用的文献
1
New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.CAR-T细胞疗法后新发严重血细胞减少症：76例复发或难治性急性淋巴细胞白血病患者的分析
Front Oncol. 2021 Jun 30;11:702644. doi: 10.3389/fonc.2021.702644. eCollection 2021.
2
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.嵌合抗原受体 T 细胞治疗血液系统恶性肿瘤患者后的长期血液学毒性。
Am J Hematol. 2021 Apr 1;96(4):455-461. doi: 10.1002/ajh.26113. Epub 2021 Feb 24.
3
CAR T cell therapies for patients with multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤患者。
Nat Rev Clin Oncol. 2021 Feb;18(2):71-84. doi: 10.1038/s41571-020-0427-6. Epub 2020 Sep 25.
4
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.接受嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤患者的造血恢复情况。
Blood Adv. 2020 Aug 11;4(15):3776-3787. doi: 10.1182/bloodadvances.2020002509.
5
Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.嵌合抗原受体 T 细胞疗法治疗复发/难治性 B 细胞恶性肿瘤患者的费用相关因素。
Cell Transplant. 2020 Jan-Dec;29:963689720919434. doi: 10.1177/0963689720919434.
6
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
7
Early and late hematologic toxicity following CD19 CAR-T cells.CD19嵌合抗原受体T细胞治疗后的早期和晚期血液学毒性
Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.
8
Role of C-Reactive Protein at Sites of Inflammation and Infection.C-反应蛋白在炎症和感染部位的作用。
Front Immunol. 2018 Apr 13;9:754. doi: 10.3389/fimmu.2018.00754. eCollection 2018.
9
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
10
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.难治性B细胞淋巴瘤中的嵌合抗原受体T细胞
N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.
Zotero 插件